Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients

Research output: Contribution to journalArticle

  • External authors:
  • Bethany Pillay
  • Danielle T. Avery
  • Joanne M. Smart
  • Theresa Cole
  • Sharon Choo
  • Damien Chan
  • Paul Gray
  • Richard Mitchell
  • Melanie Wong
  • Dianne E Campbell
  • Peter Hsu
  • John B. Ziegler
  • Jane Peake
  • Frank Alvaro
  • Capucine Picard
  • Jacinta Bustamante
  • Benedicte Neven
  • Andrew J. Cant
  • Gulbu Uzel
  • Jean-Laurent Casanova
  • Helen C. Su
  • Alexandra Freeman
  • Nirali Shah
  • Dennis D Hickstein
  • Stuart G. Tangye
  • Cindy S. Ma

Abstract

Bi-allelic inactivating mutations in DOCK8 cause a combined immunodeficiency characterised by severe pathogen infections, eczema, allergies, malignancy and impaired humoral responses. These clinical features result from functional defects in most lymphocyte lineages. Thus, DOCK8 plays a key role in immune cell function. Hematopoietic stem cell transplantation (HSCT) is curative for DOCK8 deficiency. While previous reports have described clinical outcomes for DOCK8 deficiency following HSCT, the effect on lymphocyte reconstitution and function has not been investigated. Our study determined whether defects in lymphocyte differentiation and function in DOCK8-deficient patients were restored following HSCT. DOCK8-deficient T and B lymphocytes exhibited aberrant activation and effector function in vivo and in vitro. Frequencies of αβ T and MAIT cells were reduced while γδT cells were increased in DOCK8-deficient patients. HSCT improved, abnormal lymphocyte function in DOCK8-deficient patients. Elevated total and allergen-specific IgE in DOCK8-deficient patients decreased over time following HSCT. Our results document the extensive catalogue of cellular defects in DOCK8-deficient patients, and the efficacy of HSCT to correct these defects, concurrent with improvements in clinical phenotypes. Overall, our findings provide mechanisms at a functional cellular level for improvements in clinical features of DOCK8 deficiency post-HSCT, identify biomarkers that correlate with improved clinical outcomes, and inform the general dynamics of immune reconstitution in patients with monogenic immune disorders following HSCT.

Bibliographical metadata

Original languageEnglish
JournalJournal of Clinical Investigation Insight
Early online date25 Apr 2019
DOIs
Publication statusPublished - 2019